CLR is a novel inflammatory biomarker and has been employed to serve as one of the most effective prognostic markers for pancreatic and rectal cancer surgery, tumor, and strangulated abdominal hernia (intestinal ischemia) [29,30,31,32]. The gene discussed is DCLK3; the disease is rectal cancer.